Research Study

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection
Principal Investigator 
Theodore Steiner

Overview

ClinicalTrials.gov# 
NCT03931941
Status 
Recruiting
Study Start/End 
Nov 14, 2019 to Apr 30, 2020
Locations 
Diamond Health Care Centre
Name/Title 
Jorell Gantioqui, Research Coordinator
Phone 
604-875-4111 ext.62178
Purpose of Study 

The purpose of this study is to test the safety and efficacy of RBX2660 in preventing recurrent episodes of CDI measured at 8 weeks after treatment.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.